NCT02931513 sCD163 in PBC Patients - Assessment of Treatment Response
| NCT ID | NCT02931513 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aarhus |
| Condition | Primary Biliary Cirrhosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2016-09 |
| Primary Completion | 2031-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2016-09 with a primary completion date of 2031-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed with Primary biliary cholangitis * No treatment with UDCA Exclusion Criteria: * Patient under 18 years * Expected lifetime under 6 months * Expected liver transplantation within 6 months * Liver cancer * Cirrhosis from other causes
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02931513 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Biliary Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02931513 currently recruiting?
Yes, NCT02931513 is actively recruiting participants. Contact the research team at larsbossen@clin.au.dk for enrollment information.
Where is the NCT02931513 trial being conducted?
This trial is being conducted at Aarhus C, Denmark.
Who is sponsoring the NCT02931513 clinical trial?
NCT02931513 is sponsored by University of Aarhus. The trial plans to enroll 40 participants.